王留兴, 樊青霞, 王瑞林, 吴欣爱, 宗红, 秦艳茹, 鲁培, 张蕾, 武素芳, 罗素霞, 马智勇, 王居峰, 吴敏, 周云, 万里新, 路平, 库建伟, 杨柳, 徐志巧, 王俊生, 邢国臣, 裴志东. 58例含长春瑞滨方案治疗(蒽环类/紫杉类治疗后)复发转移乳腺癌的临床观察[J]. 中国肿瘤临床, 2008, 35(24): 1388-1392.
引用本文: 王留兴, 樊青霞, 王瑞林, 吴欣爱, 宗红, 秦艳茹, 鲁培, 张蕾, 武素芳, 罗素霞, 马智勇, 王居峰, 吴敏, 周云, 万里新, 路平, 库建伟, 杨柳, 徐志巧, 王俊生, 邢国臣, 裴志东. 58例含长春瑞滨方案治疗(蒽环类/紫杉类治疗后)复发转移乳腺癌的临床观察[J]. 中国肿瘤临床, 2008, 35(24): 1388-1392.
shu
WANG Liu-xing, FAN Qing-xia, WANG Rui-lin, WU Xin-ai, ZONG Hong, QIN Yan-ru, LU Pei, ZHANG Lei, WU Su-fang, LUO Su-xia, MA Zhi-yong, WANG Ju-feng, WU Min, ZHOU Yun, WAN Li-xin, LU Ping, KU Jian-wei, YANG Liu, XU Zhi-qiao, WANG Jun-sheng, XING Guo-chen, PEI Zhi-dong. The Effects of Vinorelbine Containing Regimens on 58 Cases of Recurrent Metastatic Breast Cancer after Docetaxel and Anthracycline Treatment[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(24): 1388-1392.
Citation: WANG Liu-xing, FAN Qing-xia, WANG Rui-lin, WU Xin-ai, ZONG Hong, QIN Yan-ru, LU Pei, ZHANG Lei, WU Su-fang, LUO Su-xia, MA Zhi-yong, WANG Ju-feng, WU Min, ZHOU Yun, WAN Li-xin, LU Ping, KU Jian-wei, YANG Liu, XU Zhi-qiao, WANG Jun-sheng, XING Guo-chen, PEI Zhi-dong. The Effects of Vinorelbine Containing Regimens on 58 Cases of Recurrent Metastatic Breast Cancer after Docetaxel and Anthracycline Treatment[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 35(24): 1388-1392.
shu

58例含长春瑞滨方案治疗(蒽环类/紫杉类治疗后)复发转移乳腺癌的临床观察

The Effects of Vinorelbine Containing Regimens on 58 Cases of Recurrent Metastatic Breast Cancer after Docetaxel and Anthracycline Treatment

    摘要
  • 摘要: 目的: 观察含长春瑞滨方案对蒽环类/紫杉类药物治疗后复发转移性乳腺癌的有效性和安全性。 方法: 蒽环类/紫杉类药物治疗后复发转移性乳腺癌患者61例,其中58例可评价疗效;长春瑞滨联合顺铂(NP)41例,长春瑞滨25mg/m2,第1天和第8天,静脉滴注;顺铂75～80mg/m2,静脉滴注,分割为2～5天,3周为一周期;长春瑞滨联合卡培他滨或替加氟(NF)17例,长春瑞滨用法同NP组,卡培他滨800～1000mg/m2,分早晚两次服用,第1～14天,或替加氟600mg/m2,第2～6天,3周为一周期。化疗过程中注意观察不良反应,根据不良反应的程度调整药物用量。每两周期评价疗效。 结果: 长春瑞滨联合顺铂(NP)组,CR2例(4.9%),PR23例(56.1%),SD14例(34.1%),PD2例(4.9%),有效率为61.0%;长春瑞滨联合卡培他滨或替加氟(NF)组,CR1例(5.9%),PR8例(47.1%),SD7例(41.2%),PD1例(5.9%),有效率52.9%。常见的不良反应主要为骨髓抑制、胃肠道反应、手足综合症、神经毒性等。 结论: 含长春瑞滨方案治疗蒽环类/紫杉类药物治疗后复发转移乳腺癌疗效确切,毒性可耐受,是治疗复发转移性乳腺癌的较好方案。

     

    Abstract: Objective : To observe the efficacy and security of vinorelbine containing regimens for patients with recurrentmetastatic breast cancer after docetaxel and anthracycline treatment. Methods : A total of 61 cases were recruitedand 58 of them were evaluated. Forty-one patients received NP regimen (NVB 25mg/m2 on day 1 and day 8, DDP75-80mg/m2 in 2-5 days). The treatment was repeated every 3 weeks. Seventeen patients received NF regimen (NVB 25mg/m2 on day 1 and day 8, capecitabine 800-1000 mg/m2/d, d1-14. Three weeks was one cycle. In theNF group, capecitabine can be replaced by tegafur 600 mg/m2, d 2-6 and repeated every 3 weeks. The dose wasadjusted according to adverse effects. The efficacy was evaluated every 2 cycles. Results : In the NP group, CRwas achieved in 2 cases (4.9%), PR in 22 cases (56.1%), SD in 14 cases (34.1%), and PD in 2 cases (4.9%). Theresponse rate in the NP group was 61.0%. In the NF group, CR was achieved in 1 case (5.9%), PR in 8 cases(47.1%), SD in 7 cases (41.2%), and PD 1 case (5.9%). The response rate in the NF group was 52.9%. Thecommon toxicities included myelosuppression, gastrointestinal reactions, hand-foot syndrome and neurotoxicity. Conclusion : Vinorelbine containing regimens can achieve good results for recurrent metastatic breast cancer afterdocetaxel and anthracycline treatment, with tolerable side effects.

     

    • HTML全文
    • 参考文献(1)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回